Reprimo
From Wikipedia, the free encyclopedia
 |
This article is orphaned as few or no other articles link to it. Please help introduce links in articles on related topics. (November 2006) |
The gene reprimo has been found to be downregulated in several cancers but rarely in healthy cells. Its role appears to be related to its interaction with p53 (tumor protein 53). The gene is methylated, sometimes in pre-cancerous growths and may be an early cancer indicator. 1
Reprimo has also been foud to be associated with the develeopment of esophageal adenocarcinaoma (see Esophageal cancer), and could be a potential biomarker for early detection.2
[edit] References
- Note 1: Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M, Stastny V, Augustus M, Wu CW, Wistuba II, Meltzer SJ, Gazdar AF (2005). "Aberrant methylation of Reprimo in human malignancies". International Journal of Cancer 115 (4): 503–10. doi:. PMID 15700311.
- Note 2: Hamilton JP et al. (2006). "Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.". Clin Cancer Res. 12 (22): 6637–42. doi:. PMID : 17121882.
 |
This genetics article is a stub. You can help Wikipedia by expanding it. |
